# Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

> **NCT01895127** · PHASE2 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 11 (actual)

## Conditions studied

- Antibody-mediated Rejection
- Humoral Rejection

## Interventions

- **DRUG:** Eculizumab
- **BIOLOGICAL:** Immunoglobulin
- **PROCEDURE:** Plasmapheresis

## Key facts

- **NCT ID:** NCT01895127
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2017-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01895127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01895127, "Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01895127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*